<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Drug id="56515" name="asunercept"><HDS>Phase 2 Clinical</HDS><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><RegulatoryDesignation id="10">PRIME</RegulatoryDesignation></RegulatoryDesignations><Actions><Action id="5367" type="primary">CD95 antagonist</Action><Action id="7293" type="secondary">Synergist</Action><Action id="1545" type="secondary">Anticancer</Action><Action id="1590" type="secondary">Apoptosis inhibitor</Action><Action id="965" type="secondary">Cardiovascular agent</Action><Action id="7266" type="secondary">Cerebroprotectant</Action><Action id="396" type="secondary">Immunosuppressant</Action></Actions><Indications><Indication id="1272" type="primary">Myelodysplastic syndrome</Indication><Indication id="2454" type="primary">Glioblastoma</Indication><Indication id="725" type="primary">Solid tumor</Indication><Indication id="114" type="secondary">Sepsis</Indication><Indication id="224" type="secondary">Myocardial infarction</Indication><Indication id="616" type="secondary">Graft versus host disease</Indication><Indication id="65" type="secondary">Stroke</Indication><Indication id="651" type="secondary">Cancer</Indication></Indications><Entities><Entity>Biological</Entity></Entities><OriginatorCompany id="1033114">Apogenix GmbH</OriginatorCompany></Drug>